[go: up one dir, main page]

WO1999041279A3 - Procedes et compositions comprenant l'utilisation d'un peptide b-amyloide bloque - Google Patents

Procedes et compositions comprenant l'utilisation d'un peptide b-amyloide bloque Download PDF

Info

Publication number
WO1999041279A3
WO1999041279A3 PCT/US1999/003231 US9903231W WO9941279A3 WO 1999041279 A3 WO1999041279 A3 WO 1999041279A3 US 9903231 W US9903231 W US 9903231W WO 9941279 A3 WO9941279 A3 WO 9941279A3
Authority
WO
WIPO (PCT)
Prior art keywords
blocked
compositions
methods
amyloid peptide
present
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US1999/003231
Other languages
English (en)
Other versions
WO1999041279A2 (fr
Inventor
David G Lynn
Stephen C Meredith
Timothy S Burkoth
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Arch Development Corp
Original Assignee
Arch Development Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Arch Development Corp filed Critical Arch Development Corp
Priority to AU26004/99A priority Critical patent/AU2600499A/en
Publication of WO1999041279A2 publication Critical patent/WO1999041279A2/fr
Publication of WO1999041279A3 publication Critical patent/WO1999041279A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4711—Alzheimer's disease; Amyloid plaque core protein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • Neurology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

D'une manière générale cette invention concerne l'amyloïdogénèse, et d'une manière plus spécifique il s'agit de l'utilisation de protéines amyloïdogènes qui ont été bloquées au niveau des N- et/ou des C- termini et/ou des chaînes latérales pour empêcher leur accumulation sous forme de plaques amyloïdogènes. Des aspects particuliers de cette invention portent sur des procédés et des compositions qui empêchent la formation de plaques dans des maladies amyloïdes, telle que la maladie d'Alzheimer.
PCT/US1999/003231 1998-02-13 1999-02-12 Procedes et compositions comprenant l'utilisation d'un peptide b-amyloide bloque Ceased WO1999041279A2 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU26004/99A AU2600499A (en) 1998-02-13 1999-02-12 Methods and compositions comprising the use of blocked b-amyloid peptide

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US7465898P 1998-02-13 1998-02-13
US60/074,658 1998-02-13

Publications (2)

Publication Number Publication Date
WO1999041279A2 WO1999041279A2 (fr) 1999-08-19
WO1999041279A3 true WO1999041279A3 (fr) 1999-10-28

Family

ID=22120866

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1999/003231 Ceased WO1999041279A2 (fr) 1998-02-13 1999-02-12 Procedes et compositions comprenant l'utilisation d'un peptide b-amyloide bloque

Country Status (2)

Country Link
AU (1) AU2600499A (fr)
WO (1) WO1999041279A2 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8188046B2 (en) 2006-10-16 2012-05-29 University Of South Florida Amyloid beta peptides and methods of use

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050026165A1 (en) * 2001-05-31 2005-02-03 Cindy Orser Detection of conformationally altered proteins and prions
WO2002097444A2 (fr) 2001-05-31 2002-12-05 Arete Associates Procede de detection de proteines mal pliees
US8663650B2 (en) * 2003-02-21 2014-03-04 Ac Immune Sa Methods and compositions comprising supramolecular constructs
US7807171B2 (en) 2003-07-25 2010-10-05 Ac Immune Sa Therapeutic vaccine targeted against P-glycoprotein 170 for inhibiting multidrug resistance in the treatment of cancers
RS54074B1 (sr) * 2004-02-20 2015-10-30 Ac Immune Sa Metode i kompozicije koje sadrže supramolekulske konstrukte
CN101156068B (zh) 2005-02-15 2015-03-18 阿德利夫股份有限公司 检测错折叠蛋白和朊病毒的方法
BRPI0714930A2 (pt) * 2006-07-28 2013-05-21 Adlyfe Inc sondas peptÍdicas para fins diagnàsticos e terapÊuticos
US9289488B2 (en) 2010-08-12 2016-03-22 Ac Immune Sa Vaccine engineering
WO2012055933A1 (fr) 2010-10-26 2012-05-03 Ac Immune S.A. Préparation d'un produit de recombinaison antigénique
EP2784080B1 (fr) * 2011-10-31 2019-12-18 Shimadzu Corporation Molécule de type anticorps flexible sans charnière peptidique
US20230021187A1 (en) * 2019-11-19 2023-01-19 Foundation For Biomedical Research And Innovation At Kobe Cross-linked product of amyloid-b protein (ab) as potential substitute for amylospheroids (aspd) and analysis of aspd

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996028471A1 (fr) * 1995-03-14 1996-09-19 Praecis Pharmaceuticals Incorporated Modulateurs de l'agregation de substances amyloides
US5721106A (en) * 1991-08-13 1998-02-24 Regents Of The University Of Minnesota In Vitro method for screening β-amyloid deposition

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5721106A (en) * 1991-08-13 1998-02-24 Regents Of The University Of Minnesota In Vitro method for screening β-amyloid deposition
WO1996028471A1 (fr) * 1995-03-14 1996-09-19 Praecis Pharmaceuticals Incorporated Modulateurs de l'agregation de substances amyloides

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
BURKOTH, TIMOTHY S. ET AL: "C-Terminal PEG blocks the irreversible step in.beta.- amyloid (10-35) fibrillogenesis", J. AM. CHEM. SOC., vol. 120, no. 30, 5 August 1998 (1998-08-05), pages 7655 - 7656, XP002112798 *
ESLER WP ET AL: "Point substitution in the central hydrophobic cluster of a human beta-amyloid congener disrupts peptide folding and abolishes plaque competence", BIOCHEMISTRY, XP002113078 *
INADA Y ET AL: "Biomedical and biotechnological applications of PEG-and PM-modified proteins", TIBTECH, vol. 13, March 1995 (1995-03-01), pages 86 - 91, XP002113079 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8188046B2 (en) 2006-10-16 2012-05-29 University Of South Florida Amyloid beta peptides and methods of use

Also Published As

Publication number Publication date
WO1999041279A2 (fr) 1999-08-19
AU2600499A (en) 1999-08-30

Similar Documents

Publication Publication Date Title
WO1999041279A3 (fr) Procedes et compositions comprenant l'utilisation d'un peptide b-amyloide bloque
WO1999045907A3 (fr) Agents utilises pour traiter la maladie d'alzheimer
WO1997026919A3 (fr) Methode d'imagerie de depots amyloides
ZA99913B (en) Alteration of amino acid compositions in seeds.
CA2123739A1 (fr) Formulations contenant des carotenoides et des procarotenoides combines a des polyphenols dans la prevention des lesions dues aux anomalies de la production de radicaux libres
WO2002085903A3 (fr) Inhibiteurs d'agregation de plaque amyloide et agents d'imagerie diagnostique
MX9504067A (es) Composiciones cosmeticas que contienen un compuesto lipido del tipo ceramida y un peptido con una cadena grasa y sus usos.
WO1995021601A3 (fr) Proteines de 'domaine de kunitz' a activite antikallikreine, et leurs analogues
CA2304969A1 (fr) Composition bucco-dentaire pour le traitement de la mauvaise haleine
EP1166767A3 (fr) Produit pour le soin de la peau contenant de la hydroxypoline ou des dérivés de la N-acétyl hydroxyproline
CA2284170A1 (fr) Identification d'agents utiles dans le traitement de la maladie d'alzheimer
BR9910490A (pt) Materiais e métodos para criar insetos, ácaros e outros organismos benéficos
PT1095061E (pt) Péptidos baseados na sequência da lactoferrina humana e sua utilização
CA2290101A1 (fr) Utilisation de la tourmaline dans des compositions cosmetiques de nettoyage
CA2071146A1 (fr) Compositions d'hygiene buccale legere a saveur soutenue
CA2309351A1 (fr) Compositions de nettoyage administrables par voie orale et leurs procedes d'utilisation
ATE174786T1 (de) Orale präparate zur behandlung von plaque und gingivitis, die einen nicht-kationischen antibakteriellen wirkstoff und ein bikarbonatsalz enthalten
MXPA03003741A (es) Metodos y composiciones para el tratamiento de enfermedades oftalmicas.
WO1998032428A3 (fr) Compositions a base de choline et utilisation de la choline pour traiter les chocs endotoxiques
DE60221989D1 (de) Mundpflegemittel enthaltend einen fluor-ion-vektor und ein antioxidationsmittel
YU45103A (sh) Upotreba sarp/1 za lečenje i prevenciju skleroderme
WO2001043705A3 (fr) Compositions a base de retinoides et de stilbenes pour le soin de la peau
DK1617729T3 (da) Kaffesammens tninger
CA2241825A1 (fr) Nouveaux derives d'edta, de dtpa et de ttha monofonctionnalises et leur utilisation en medecine pour la therapie et le diagnostic
MXPA04006498A (es) Indanos e indanonas y su uso en perfumeria.

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: A3

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
NENP Non-entry into the national phase

Ref country code: KR

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase